person · Reporting owner
Hanley Jr. Michael Conick
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alto Neuroscience, Inc.ANRO · Entity 4755 | CHIEF OPERATING OFFICER | February 11, 2026 | February 13, 2026 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Chief Business Officer | February 23, 2023 | February 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alto Neuroscience, Inc.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.71 · Expires 2036-02-10 | Direct | 131,000 |
Reported balance
After 2026-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 131,000 · Balance 131,000 F1: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Spyre Therapeutics, Inc.
Report date February 23, 2023 · Filed February 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2033-02-22 | Direct | 500,000 |
Reported balance
After 2023-02-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-23 · Grant · Acquired 500,000 · Balance 500,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2026 Filed Feb 13, 2026 22:17 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 131,000 | $0.00 Strike: $16.71 | $0.00 |
DisclosureSEC source: 0001791413-26-000001 · wk-form4_1771021048.xml · derivative · entry 1 Hanley Jr. Michael Conick · CIK 0001791413 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 131,000 shares Expires 2036-02-10 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0001999480-25-000065 · wk-form4_1752009762.xml · derivative · entry 6 Hanley Jr. Michael Conick · CIK 0001791413 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2035-02-04 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F5 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000065 · wk-form4_1752009762.xml · derivative · entry 5 Hanley Jr. Michael Conick · CIK 0001791413 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-02-04 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F5 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 188,000 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0001999480-25-000065 · wk-form4_1752009762.xml · derivative · entry 4 Hanley Jr. Michael Conick · CIK 0001791413 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 188,000 shares Expires 2034-05-19 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F4 · derivative.exercise_date: 25% of the shares underlying the option vested on May 20, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 188,000 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000065 · wk-form4_1752009762.xml · derivative · entry 3 Hanley Jr. Michael Conick · CIK 0001791413 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,000 Underlying: Common Stock · 188,000 shares Expires 2034-05-19 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F4 · derivative.exercise_date: 25% of the shares underlying the option vested on May 20, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 8,000 | Not disclosed Strike: $14.88 | Not disclosed |
DisclosureSEC source: 0001999480-25-000065 · wk-form4_1752009762.xml · derivative · entry 2 Hanley Jr. Michael Conick · CIK 0001791413 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2034-02-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| July 03, 2025 Filed Jul 8, 2025 21:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,000 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0001999480-25-000065 · wk-form4_1752009762.xml · derivative · entry 1 Hanley Jr. Michael Conick · CIK 0001791413 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2034-02-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date. F3 · price: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:22 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001999480-25-000016 · wk-form4_1738963366.xml · derivative · entry 1 Hanley Jr. Michael Conick · CIK 0001791413 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 20, 2024 Filed May 22, 2024 21:19 UTC | Alto Neuroscience, Inc. ANRO · Entity 4755 | GrantEmployee Stock Option (right to buy) · Derivative | 188,000 | $0.00 Strike: $12.40 | $0.00 |
DisclosureSEC source: 0001415889-24-014118 · form4-05222024_090504.xml · derivative · entry 1 Hanley Jr. Michael Conick · CIK 0001791413 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,000 Underlying: Common Stock · 188,000 shares Expires 2034-05-19 F1 · derivative.exercise_date: 25% of the shares underlying the option shall vest on May 20, 2025, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 23:22 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001209191-23-012877 · doc4.xml · derivative · entry 1 Hanley Jr. Michael Conick · CIK 0001791413 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-02-22 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 23, 2022 Filed Aug 25, 2022 23:35 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001209191-22-047649 · doc4.xml · derivative · entry 1 Hanley Jr. Michael Conick · CIK 0001791413 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2032-08-22 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48 of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 22:24 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | PurchaseCommon Stock | 28,200 | $0.71 | $20,022.00 |
DisclosureSEC source: 0001209191-22-036085 · doc4.xml · nonDerivative · entry 1 Hanley Jr. Michael Conick · CIK 0001791413 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,200 F1 · balance_after: Includes 8,000 shares of common stock acquired by the Reporting Person pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:51 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 160,000 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-22-011708 · doc4.xml · derivative · entry 1 Hanley Jr. Michael Conick · CIK 0001791413 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-02-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:07 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001209191-21-012423 · doc4.xml · derivative · entry 1 Hanley Jr. Michael Conick · CIK 0001791413 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2021, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 22:12 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001567619-20-004315 · doc1.xml · derivative · entry 1 Hanley Jr. Michael Conick · CIK 0001791413 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 21, 2019 Filed Oct 23, 2019 20:09 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $7.79 | $0.00 |
DisclosureSEC source: 0001567619-19-019922 · doc1.xml · derivative · entry 1 Hanley Jr. Michael Conick · CIK 0001791413 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2029-10-20 F1 · derivative.exercise_date: The options will vest as to 1/4th of the total shares on October 21, 2020, and then 1/48th of the shares monthly thereafter, such that the option is fully vested on October 21, 2023, subject to the Reporting Person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.